On Monday, Novo Nordisk (NYSE: NVO) said an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.
The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack, and stroke, by 14% compared to placebo, meeting the main goal of the trial.
The study tested the drug as an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease, the company said.
Novo Nordisk (NYSE: NVO) expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.
The drugmaker said detailed results from the study will be presented at a scientific conference next year.
(Source: ReutersReuters)
